 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumabTM, today announced that the Companys management will present and host meetings with investors and potential partners at the J.P. Morgan Healthcare Conference, held virtually from January 11 to 14, 2021. Cameron Durrant, MD, MBA, chief executive off 